Stacy Telloni, MD
Medical Oncology · Raleigh, NCNPI 1922241165
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (55.4%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Novartis at 56.2% of the total. 2025 is the largest year on record at $1,011, more than ten times the $12 reported in 2019.
Across 16 payments — averaging $112.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Daiichi Sankyo Inc.$550
- Covis Pharma GmbH$200
- Inari Medical, Inc.$15
- Pfizer$12
- Gilead$12
Across 1 payment — averaging $41,182 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$41K
What the payments were for
- Consulting fees$20011%
- Speaking & faculty fees$55031%
- Food & beverage$292%
- Education$241%
- Other$99755%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 11 | $1,011 |
| Daiichi Sankyo Inc. | 1 | $550 |
| Covis Pharma GmbH | 1 | $200 |
| Inari Medical, Inc. | 1 | $15 |
| Pfizer | 1 | $12 |
| Gilead | 1 | $12 |
How this compares
$1,800 in reported general payments places this provider in the 55th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 36 | $596,279 |
| KisqaliRibociclib Succinate | 17 | $286,943 |
| TruqapCapivasertib | 11 | $150,725 |
| EliquisApixaban | 22 | $20,617 |
| Exemestane | 29 | $7,688 |
| Letrozole | 293 | $6,554 |
| Anastrozole | 184 | $3,685 |
| Tamoxifen Citrate | 81 | $2,087 |
| Estradiol | 18 | $1,315 |
| Gabapentin | 84 | $1,309 |
| Celecoxib | 38 | $1,167 |
| Oxycodone Hcl | 67 | $1,106 |
| Duloxetine Hcl | 44 | $952 |
| Ibandronate Sodium | 19 | $730 |
| Lidocaine | 11 | $649 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $12 | $616,89558 claims |
| NovartisKisqali | $1,011 | $286,94317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 170 medical oncology providers in North Carolina.
Other medical oncology in Raleigh
- Thomas LeblancDurham$1.7M
- David RizzieriCharlotte$714K
- Raghava InduruAlbemarle$625K
- Nilanjan GhoshCharlotte$510K
- Mohamed SalemCharlotte$396K
- Andrew ArmstrongDurham$377K
- John StricklerDurham$319K
- Neal ReadyDurham$309K
- Thomas StinchcombeChapel Hill$281K
- Steven SorscherWinston Salem$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.